Quantification of Blood Caffeine Levels in Patients With Parkinson's Disease and Multiple System Atrophy by Caffeine ELISA
Caffeine is considered to be a neuroprotective agent against Parkinson's disease (PD) and is expected to offer a blood-based biomarker for the disease. We herein investigated the ability of this biomarker to discriminate between PD and neurodegenerative diseases. To quantify caffeine concentrat...
Main Authors: | Takuma Ohmichi, Takashi Kasai, Makiko Shinomoto, Jun Matsuura, Takashi Koizumi, Fukiko Kitani-Morii, Harutsugu Tatebe, Hidenao Sasaki, Toshiki Mizuno, Takahiko Tokuda |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2020.580127/full |
Similar Items
-
Cerebral spinal fluid biomarker profiles in CNS infection associated with HSV and VZV mimic patterns in Alzheimer’s disease
by: Makiko Shinomoto, et al.
Published: (2021-01-01) -
Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy.
by: Takashi Kasai, et al.
Published: (2016-01-01) -
Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease.
by: Takuma Ohmichi, et al.
Published: (2018-01-01) -
Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
by: Yuta Kojima, et al.
Published: (2021-01-01) -
Caffeine and caffeine hydrate (first revision)
by: 982 SIRIM